This is what I wrote in SA: "Until CytoDyn stop
Post# of 154867
(Total Views: 413)
Posted On: 10/25/2019 3:05:57 PM
This is what I wrote in SA:
"Until CytoDyn stops this nonsense of reaching beyond its grasp and can prove that it has a credible licensing deal with a Gilead (GILD), a GlaxoSmithKline (GSK) or an AbbVie (ABBV), it is likely to continue to underperform.": I disagree with this. There are many companies out there that can benefit from a partnership with CYDY. You "forgot" to mention that there is a rolling BLA and the company will likely get Pro-140 approved for combo therapies very soon.
Also, the expenditures in pursuing other indications have been minimal (low tens of thousand per indication).
Management have been trying hard to break a deal and, possibly, one is in the works. Whatever the case might be, a de-risked drug like Leronlimab is worth a lot.
BTW: "which it claims to have blockbuster potential" is not a honest statement. The drug is superior to other drugs in the market (no serious secondary effects). If in doubt, please ask the FDA. It has blockbuster potential if approved.
Your article is not balanced, solely depicts a dismal economic situation (correctly), but fails to portray the results of many years of financing and dilutions: one drug end of p3, very advanced as Mono (first in class) and several in p2. This is the story of many (today successful) biotech companies..
"Until CytoDyn stops this nonsense of reaching beyond its grasp and can prove that it has a credible licensing deal with a Gilead (GILD), a GlaxoSmithKline (GSK) or an AbbVie (ABBV), it is likely to continue to underperform.": I disagree with this. There are many companies out there that can benefit from a partnership with CYDY. You "forgot" to mention that there is a rolling BLA and the company will likely get Pro-140 approved for combo therapies very soon.
Also, the expenditures in pursuing other indications have been minimal (low tens of thousand per indication).
Management have been trying hard to break a deal and, possibly, one is in the works. Whatever the case might be, a de-risked drug like Leronlimab is worth a lot.
BTW: "which it claims to have blockbuster potential" is not a honest statement. The drug is superior to other drugs in the market (no serious secondary effects). If in doubt, please ask the FDA. It has blockbuster potential if approved.
Your article is not balanced, solely depicts a dismal economic situation (correctly), but fails to portray the results of many years of financing and dilutions: one drug end of p3, very advanced as Mono (first in class) and several in p2. This is the story of many (today successful) biotech companies..
(4)
(0)